Pulmonary Fibrosis Study
What is Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a disease of inflammation that results in scarring, or fibrosis, of the lungs. In time, this fibrosis can build up to the point where the lungs are unable to provide oxygen to the tissues of the body. Doctors use the word "idiopathic" (from the Greek "idio" meaning "peculiar" or "unusual" and "pathy" meaning "illness") to describe the disease, because the cause of IPF is unknown. Currently, researchers believe that IPF may result from either an autoimmune disorder, a condition in which the body's immune system attacks its own tissues, or the after effects of an infection, most likely a virus. Whatever the trigger is for IPF, it appears to set off a series of events in which the inflammation and immune activity in the lungs and, eventually, the fibrosis processes, does not shut off like it's supposed to. In a few cases, heredity appears to play a part, possibly making some individuals more likely than others to get IPF. In studies of patients with IPF, the average survival rate has been found to be 4 to 6 years after diagnosis. Those who develop IPF at a young age seem to have a longer survival.
Idiopathic Pulmonary Fibrosis Clinical Trials
Fibrogen (FGLC-3019-067): A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis.
Purpose: To evaluate the safety and tolerability of FG-3019 in subjects with IPF, and the efficacy of FG-3019 in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these subjects. Participation could last approximately 2 years.
RIFF (GB28547): A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Idiopathic Pulmonary Fibrosis.
Purpose: This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in patients with idiopathic pulmonary fibrosis. Patients will be randomized to receive either lebrikizumab or placebo subcutaneously every 4 weeks.
Lebrickizumab is an injectable medication given every 4 weeks intended to slow the progression of IPF. Participation could last from 1 to 2.5 years.
RAINIER (GS-US-322-0207):A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF).
Purpose: The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis.
Simtuzamab is a weekly injectable medication intended to slow the progression of IPF. Participation could last up to 3.5 years.
Patient Brochure - PDF
IM136003: Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis.
Purpose: The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF). Participation could last up to 34 weeks.
Clinical Trials (Closed to Enrollment):
BIPI 1199.33 Extension: An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF).
Purpose: The aim of this extension trial is to assess the long-term safety of BIBF 1120 treatment in patients with Idiopathic Pulmonary Fibrosis who have completed one year treatment and the follow up period in the double-blind phase III placebo controlled parent trials (1199.32 and 1199.34), who wish to continue treatment with BIBF 1120.
Status: Active, Not Recruiting Patients
FIBROGEN (FG-3019-049): A Phase 2, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of FG-3019 in Subjects With Idiopathic Pulmonary Fibrosis
Purpose: To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
Status: Active, Not Recruiting Patients
Pulmonary Function Testing (PFT)
|For All Studies:
Qualified participants will receive study-related care, study-related exams and study-related medication at no cost. Participants may be compensated for their time and travel.
If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email: firstname.lastname@example.org.